Fixed drug eruption to rofecoxib with cross-reactivity to sulfonamides

Dermatology

Volumn 203, Issue 4, 2001, Pages 351-

  Kaur, Charandeep ^a   Sarkar, Rashmi ^a   Kanwar, Amrinder J ^a  

^a GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Cyclooxygenase 2 inhibitor; Fixed drug eruption; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; BETAMETHASONE DIPROPIONATE; CELECOXIB; COTRIMOXAZOLE; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; ANGIONEUROTIC EDEMA; CASE REPORT; CROSS REACTION; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG ERUPTION; DRUG MECHANISM; DRUG USE; EROSION; ERYTHEMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERPIGMENTATION; KNEE INJURY; LETTER; LIP; MALE; NAUSEA; PRIORITY JOURNAL; PROVOCATION TEST; SKIN ALLERGY; SKIN EDEMA; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ADULT; CROSS REACTIONS; CYCLOOXYGENASE INHIBITORS; DRUG ERUPTIONS; HUMANS; LACTONES; MALE; SULFONAMIDES; SULFONES;

EID: 18244388255     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051790     Document Type: Letter

References (5)

1. Rofecoxib [Vioxx, MK-0966; 4-(4-methylsulfonyl]phenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
2. Rofecoxib
3. Allergic skin reaction to celecoxib
4. COX-2 selective nonsteroidal anti-inflammatory drugs - Do they really offer any advantage?
5. Immunological tolerability profile of celecoxib